Anticancer research · 2013
Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mastronuzzi Angela, Del Bufalo Francesca, Iacono Anna, Secco Domitilla Elena, Serra Annalisa, Colafati Giovanna Stefania, DE Ioris Maria Antonietta, Corsetti Tiziana
Аннотация
BACKGROUND: Relapsed medulloblastoma (MB) is a highly lethal disease, requiring for new effective treatment strategies. Intrathecal (IT) therapy both for de novo or relapsed brain tumors with meningeal metastasis is rarely used in first line and relapse protocols.
PATIENTS AND METHODS: We report on three cases of children with relapsed MB treated with IT liposomal cytarabine administered after mild sedation every 15 days.
RESULTS: The treatment was well-tolerated in all patients, achieving a prolonged progression-free survival (4-11 months) with a good quality of life.
CONCLUSION: This experience suggests the need for a phase II trial in brain embryonal tumors with leptomeningeal metastasis to better evaluate the efficacy of IT liposomal cytarabine.
PATIENTS AND METHODS: We report on three cases of children with relapsed MB treated with IT liposomal cytarabine administered after mild sedation every 15 days.
RESULTS: The treatment was well-tolerated in all patients, achieving a prolonged progression-free survival (4-11 months) with a good quality of life.
CONCLUSION: This experience suggests the need for a phase II trial in brain embryonal tumors with leptomeningeal metastasis to better evaluate the efficacy of IT liposomal cytarabine.